Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.4
Journals
Cancers
Special Issues
Advances in Pancreatoduodenectomy
cancers-logo
Submit to Cancers Review for Cancers Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Advances in Pancreatoduodenectomy

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".

Deadline for manuscript submissions: closed (31 October 2025) | Viewed by 2894

Special Issue Editors

Prof. Dr. Chang Moo Kang

E-Mail Website
Guest Editor
Department of Hepatobiliary and Pancreatic Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea
Interests: pancreatic cancer; pancreatectomy; laparoscopic; robotic
Prof. Dr. Jae Hoon Lee

E-Mail Website
Guest Editor
Division of Hepatobiliary and Pancreas Surgery, Department of Surgery, Asan Medical Center, Ulsan University, Seoul, Republic of Korea
Interests: pancreatic surgery; robotic; pancreatic cancer; biliary cancer

Special Issue Information

Dear Colleagues,

In the past, pancreatoduodenectomy (PD) was once regarded as a surgical procedure to be avoided because of high morbidity and mortality rates. However, with advances in surgical experiences, techniques, profound anatomy knowledge, and the quality of perioperative management, PD is gold-standard in treating periampullary pathological lesions. In addition, the minimally invasive surgical approach, laparoscopic or robotic, has recently became one a hot topic in dealing with advances in PD.

I am very excited to invite you to contribute your expertise and insights to this groundbreaking compilation. This Special Issue aims to provide a comprehensive overview of recent advances, innovations, and breakthroughs in the field of pancreatoduodenectomy. We seek to explore the latest surgical techniques, technological advancements, perioperative management strategies, and outcomes research related to this critical aspect of cancer treatment. This Special Issue welcomes reviews, as well as original research articles, by August 15, 2024.

Prof. Dr. Chang Moo Kang
Prof. Dr. Jae Hoon Lee
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • surgical innovations and techniques in pancreatoduodenectomy
  • surgical anatomy to understand pancreatoduodenectomy
  • advances in preoperative imaging and planning
  • perioperative care and complications management
  • oncologic outcomes and long-term survival studies
  • multidisciplinary approaches to enhance patient outcomes
  • emerging technologies and their impact on surgical precision

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

17 pages, 284 KB  
Review
Minimally Invasive Pancreatoduodenectomy for Pancreatic Cancer: Current Perspectives and Future Directions
by Munseok Choi and Chang Moo Kang
Cancers 2026, 18(2), 197; https://doi.org/10.3390/cancers18020197 - 7 Jan 2026
Viewed by 359
Abstract
Background: Minimally invasive pancreatoduodenectomy (MIPD) has evolved from an experimental technique to a feasible surgical option for pancreatic cancer in selected settings. However, its oncologic adequacy, safety, and generalizability remain debated, particularly given the biological aggressiveness of pancreatic ductal adenocarcinoma (PDAC) and the [...] Read more.
Background: Minimally invasive pancreatoduodenectomy (MIPD) has evolved from an experimental technique to a feasible surgical option for pancreatic cancer in selected settings. However, its oncologic adequacy, safety, and generalizability remain debated, particularly given the biological aggressiveness of pancreatic ductal adenocarcinoma (PDAC) and the technical complexity of the procedure. Methods: This narrative review critically summarizes contemporary evidence regarding MIPD for pancreatic cancer, with particular attention to randomized controlled trials (RCTs), meta-analyses, and large observational studies. We distinguish findings derived from mixed periampullary tumor cohorts from those specific to PDAC and evaluate methodological limitations, learning-curve effects, and sources of heterogeneity across studies. Results: Recent RCTs and meta-analyses demonstrate that, when performed by experienced surgeons in high-volume centers, MIPD achieves perioperative outcomes comparable to open pancreatoduodenectomy, with advantages including reduced blood loss, shorter hospital stay, and faster functional recovery. Importantly, oncologic parameters such as R0 resection rates and lymph node yield appear equivalent between approaches, although robust long-term survival data from PDAC-specific RCTs remain lacking. Emerging evidence supports the feasibility of MIPD in complex clinical scenarios, including after neoadjuvant therapy, in frail or elderly patients, and in selected cases requiring vascular resection. Nonetheless, outcomes are strongly influenced by surgeon experience, institutional volume, and patient selection. Cost-effectiveness analyses and data from lower-volume centers remain limited. Conclusions: Current evidence supports MIPD as a viable alternative to open surgery for pancreatic cancer in carefully selected patients treated at specialized centers. However, claims of oncologic superiority are premature. Future research should focus on PDAC-specific randomized trials, standardized quality metrics, and strategies to mitigate learning-curve and resource-related barriers to broader implementation. Full article
(This article belongs to the Special Issue Advances in Pancreatoduodenectomy)
10 pages, 247 KB  
Review
Technical Feasibility of Microwave Ablation in Pancreatic Tumors: A Scoping Review of Procedural Efficacy and Safety
by Daniela Tabacelia, Carlos Robles-Medranda, Artsiom Klimko, Stephen P. Pereira, Peter Vilmann, Rogier P. Voermans, Adrian Săftoiu, Cristian George Tieranu and Cezar Stroescu
Cancers 2025, 17(7), 1197; https://doi.org/10.3390/cancers17071197 - 31 Mar 2025
Viewed by 1841
Abstract
Background/Objectives: Pancreatic cancer remains one of the most aggressive and lethal malignancies, with limited effective treatment options for advanced stages. Microwave Ablation (MWA) has emerged as a minimally invasive therapeutic modality, offering potential benefits in tumor control. This review aims to critically assess [...] Read more.
Background/Objectives: Pancreatic cancer remains one of the most aggressive and lethal malignancies, with limited effective treatment options for advanced stages. Microwave Ablation (MWA) has emerged as a minimally invasive therapeutic modality, offering potential benefits in tumor control. This review aims to critically assess the safety and efficacy of MWA in the treatment of pancreatic cancer, focusing on its application in various pancreatic lesions. Methods: We systematically reviewed studies published between 2010 and 2023 that evaluated the use of MWA in pancreatic tumors, including locally advanced pancreatic cancer (LAPC), pancreatic neuroendocrine tumors (PNETs), and pancreatic metastases from renal cell carcinoma (RCC). Due to limited data on survival rates and long-term outcomes, our analysis concentrated primarily on the technical aspects and immediate procedural outcomes of MWA. Results: MWA was technically feasible in all cases. The overall complication rate was approximately 16.7% (nine patients), with higher incidences in tumors located in the pancreatic head. Reported complications included pancreatitis and pseudocyst formation. Procedural parameters varied, with applied energy ranging from 20 to 80 watts and ablation times between 2 to 15 min, depending on the microwave generator type and approach (percutaneous, intraoperative or endoscopic). All cases demonstrated effective necrosis of the target tissue, and several studies reported notable tumor size reductions, averaging up to 70%. Conclusions: MWA shows promise as a therapeutic option for pancreatic cancer, achieving high technical success rates and significant tumor reductions. However, the procedure is associated with a moderate complication rate, particularly in tumors located in the pancreatic head. Full article
(This article belongs to the Special Issue Advances in Pancreatoduodenectomy)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop